Anuncio de seguridadInformación adicional para pacientesInformación adicional para profesionales de la saludResumen de Datos  Anuncio de seguridad El 21 de julio de 2011, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) continúa con la revisión de los datos de estudios publicados para evaluar si el uso de los bifosfonatos por vÃa oral…
Comunicado de seguridad de medicamentos de la FDA: Continúa la revisión de seguridad de los medicamentos por vía oral para la osteoporosis (bifosfonatos) en relación con un probable mayor riesgo de cáncer de esófago
Anuncio de seguridadInformación adicional para pacientesInformación adicional para profesionales de la saludResumen de Datos  Anuncio de seguridad El 21 de julio de 2011, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) continúa con la revisión de los datos de estudios publicados para evaluar si el uso de los bifosfonatos por vÃa oral…
FDA Drug Safety Communication: FDA alerts healthcare professionals to stop performing heart scans with CardioGen-82 due to potential for increased radiation exposure in patients
<!– –> <!– Page Last Updated: 07/26/2011 –> Page Last Updated: 07/26/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications
Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary References  here.  Although the exact mechanism of this drug interaction is unknown, methylene blue inhibits the action of monoamine oxidase A—an enzyme responsible for breaking down serotonin in the brain. It is believed that when methylene blue is given to patients taking serotonergic…
FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications
 Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary References  here.  Although the exact mechanism of this drug interaction is unknown, linezolid inhibits the action of monoamine oxidase A—an enzyme responsible for breaking down serotonin in the brain. It is believed that when linezolid is given to patients taking serotonergic psychiatric medications,…
FDA Drug Safety Communication: Chantix (varenicline) drug label now contains updated efficacy and safety information
The following announcement is related to planned labeling changes that were described in the recent FDA Drug Safety Communication on Chantix (varenicline) issued on 6/16/2011. [7-22-2011] The U.S. Food and Drug Administration (FDA) has approved an updated drug label for the smoking cessation aid Chantix (varenicline) to include information about the efficacy and safety of…
Inactive Ingredients Database Download
<!– –> <!– Page Last Updated: 07/21/2011 –> Page Last Updated: 07/21/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events
 Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [07-21-2011] The U.S. Food and Drug Administration (FDA) is reviewing data from a clinical trial that was evaluating the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation. The study was stopped early after the data monitoring…
FDA Drug Safety Communication: Ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer
 Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [07-21-2011] The U.S. Food and Drug Administration (FDA) is continuing to review data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus (esophageal cancer). There have been conflicting…
FDA Drug Safety Communication: Increased radiation exposure due to undetected strontium breakthrough when using CardioGen-82 for cardiac positron emission tomography (PET) scans
<!– –> <!– Page Last Updated: 07/15/2011 –> Page Last Updated: 07/15/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.